U.S. Metals and Mining Stock News

Recent hedge fund activity around Yum! Brands (YUM) is converging with a fresh menu push at Taco Bell, as several large investors add exposure while the company permanently adds Nacho Fries and more than 20 new items. See our latest analysis for Yum! Brands. Yum! Brands' share price is at US$159.10 after a 2.8% one day share price decline, although the 5.7% year to date share price return and 63.1% five year total shareholder return suggest momentum has persisted over longer periods. If you...

Tsakos Energy Navigation (TEN) is in focus after reporting fourth quarter 2025 net income of US$58.01 million with basic EPS of US$1.70, alongside full year earnings and a reshuffle of senior finance roles. See our latest analysis for Tsakos Energy Navigation. Recent trading reflects that story, with a 26.31% 1 month share price return, a 61.64% 3 month share price return and a 124.43% 1 year total shareholder return, suggesting momentum has been building around earnings and the CFO reshuffle...

If you are wondering whether Diamondback Energy's current share price still lines up with its underlying worth, the next sections will walk through what the numbers are actually saying about value. The stock last closed at US$189.68, with returns of 7.4% over 7 days, 12.1% over 30 days, 24.5% year to date, 23.6% over 1 year, 65.6% over 3 years, and 215.1% over 5 years. This naturally raises questions about how much of this is already reflected in the valuation. Recent coverage has focused on...

Bank7 (BSVN) FY 2025 earnings snapshot Bank7 (BSVN) has wrapped up FY 2025 with fourth quarter revenue of US$24.1 million and basic EPS of US$1.14, while trailing 12 month revenue came in at US$95.7 million and EPS at US$4.56. Over the past six quarters, revenue has ranged between US$22.6 million and US$24.9 million per quarter as EPS moved between US$1.10 and US$1.26. This gives you a clear line of sight on how the top line and per share profits have tracked into the latest print. With a net...

In March 2026, Microvast Holdings, Inc. reported fourth-quarter 2025 sales of US$96.4 million, full-year sales of US$427.52 million, a sharply lower annual net loss of US$29.22 million, and issued 2026 guidance pointing to continued revenue growth while citing tariff, regulatory, and geopolitical headwinds. On the same day, auditor Deloitte Touche Tohmatsu CPA Ltd issued an unqualified opinion but raised doubt about Microvast’s ability to continue as a going concern, highlighting a tension...

General Mills (GIS) has just posted its Q3 2026 numbers, with revenue at US$4.4b and basic EPS of US$0.57, set against a trailing twelve month EPS of US$4.07 on revenue of US$18.4b. Over recent quarters the company has seen revenue move from US$4.8b in Q2 2026 and US$4.5b in Q1 2026 to the latest US$4.4b print, while basic EPS shifted from US$0.77 and US$2.22 in those periods to US$0.57. This sets up a results season where investors are likely to focus squarely on how margins are holding up...

Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for this condition and has already generated significant initial sales. The successful launch marks a material commercial milestone for Insmed and adds a new revenue stream alongside its existing portfolio. Insmed focuses on treatments for serious and rare respiratory diseases, so the approval and rollout of Brinsupri fit directly into its...

Carter's (CRI) has attracted investor attention after recent trading saw the share price at $34.51, with mixed return patterns over the past year prompting closer scrutiny of the childrenswear company’s fundamentals and valuation. See our latest analysis for Carter's. The recent pullback, including a 13.83% 1 month share price return and an 11.67% 1 year total shareholder return, suggests momentum has cooled after a modest 3.95% year to date share price gain. If Carter's price action has you...

Capital Clean Energy Carriers (CCEC) recently sold 12 container vessels, raised about US$472.2 million in net proceeds, and redirected that capital into gas transportation assets, including newbuilding LNG carriers on long-term charters. See our latest analysis for Capital Clean Energy Carriers. Despite the recent asset sales and LNG charter wins, the share price is around US$20.21 with a 30 day share price return of about an 11% decline. The 1 year total shareholder return of 5.67% and 3...

Walker & Dunlop stock moves after extended share price slide Walker & Dunlop (WD) is drawing fresh attention after a sharp share price slide, with the stock showing negative returns over the past month, past 3 months, year to date, and past year. See our latest analysis for Walker & Dunlop. The 30 day share price return of 27.48% and 90 day share price return of 27.21% underline a clear loss of momentum. At the same time, the 1 year total shareholder return of 45.38% and 5 year total...

If you are wondering whether Reddit's current share price really reflects what you are getting as an investor, this article looks closely at what the numbers indicate about value. Reddit recently closed at US$142.79, with returns of 4.1% over the last 7 days, 2.2% over 30 days, a 41.0% decline year to date, and 29.9% over the last year. Recent headlines have focused on Reddit's position as a major online community platform and its ongoing role in broader market conversations. These stories...

comScore FY 2025 earnings snapshot comScore (SCOR) just closed out FY 2025 with Q4 revenue of US$93.5 million and basic EPS of US$12.77, alongside full year trailing twelve month figures showing revenue of US$357.5 million and a net loss of US$101.8 million. Over recent quarters the company has seen revenue move in a narrow band between US$85.7 million and US$94.9 million per quarter. At the same time, basic EPS has swung from a loss of US$12.79 to a profit of US$12.77. This leaves investors...

Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third quarter of 2026. See our latest analysis for Spyre Therapeutics. At a share price of $43.06, Spyre’s momentum has been strong, with a 30 day share price return of 17.55% and a 90 day gain of 28.65%. The 1 year total shareholder return of 134.02% and 3 year total shareholder return above 4x...

Infleqtion (NYSE:INFQ) has delivered the UK’s first operational 100-qubit quantum computer to the National Quantum Computing Centre. The system is based on Infleqtion’s Sqale platform and is the only operational 100-physical-qubit quantum computing system currently installed in a UK national facility. This deployment gives UK researchers and industry direct access to larger scale neutral atom hardware for benchmarking and application testing. For investors watching quantum hardware,...

Earlier this month, Littelfuse, Inc. amended and restated its credit agreement, increasing its senior unsecured revolving credit facility from US$700 million to US$800 million and extending the maturity to March 12, 2031, while also appointing Trane Technologies executive Holly B. Paeper to its board and Technology Committee. The larger, longer-dated revolving credit line and addition of a board member with deep electrification and thermal management experience could shape how Littelfuse...

Palomar Holdings (NasdaqGS:PLMR) reported strong fourth quarter results, with revenue figures that were materially ahead of earlier analyst expectations. The quarter highlighted performance in the company’s catastrophe insurance focus, an area closely watched by investors given recent weather and loss events. This update reflects current operating momentum for Palomar’s specialty insurance franchise and has not been widely discussed in recent coverage. Palomar focuses on specialty and...

Amneal Pharmaceuticals (AMRX) is back in focus after reporting 2025 results, with revenue of US$3.02b, operating income of US$421m, and lower net leverage of 3.5x, alongside 2026 guidance pointing to adjusted EBITDA and EPS growth. See our latest analysis for Amneal Pharmaceuticals. The recent pullback, including a 16.4% 1 month share price return decline to US$12.39, sits against a much stronger backdrop. The 1 year total shareholder return is 41.9%, and the 3 year total shareholder return...

If you are wondering whether Mercury General at around US$87.85 is still offering value or if most of the opportunity has already played out, this overview helps you frame that question clearly. The stock has pulled back with a 0.8% decline over 7 days and a 6.0% decline over 30 days, following very strong returns of 56.5% over 1 year, 216.2% over 3 years and 71.8% over 5 years. Recent attention around the stock has focused on its longer term share price performance and how that compares...

Event context and recent price performance Veralto (VLTO) has been on investors’ radar after recent share price weakness, with the stock down about 11% over the past 3 months and roughly 9% over the past year. See our latest analysis for Veralto. With the share price at $89.99 and a 90 day share price return of 10.7% and 1 year total shareholder return of 8.9%, recent weakness suggests momentum has been fading as investors reassess growth prospects and risk. If this kind of pullback has you...

In March 2026, Gambling.com Group reported that fourth-quarter 2025 sales rose to US$46.24 million and full-year 2025 sales reached US$165.45 million, but the company swung to a full-year net loss of US$32.93 million after recording a US$14.01 million impairment on intangible assets. Alongside these results, the company completed a share buyback of 3,960,663 shares for US$35.58 million and issued 2026 revenue guidance of US$170 million to US$180 million, highlighting a growing focus on data...

If you are wondering whether Cognizant Technology Solutions at around US$60.29 is a bargain or a value trap, the key is to look closely at what the current price actually implies. The stock has recorded a 3.4% decline over the last 7 days and a 9.4% decline over the last 30 days, contributing to a 25.8% decline year to date and a 23.0% decline over the last year. The 3 year return is 10.4%, and the 5 year return is a 15.2% decline. These moves have put valuation in the spotlight, with...

In March 2026, Sabine Royalty Trust reported monthly production of 49,137 barrels of oil and 931,107 Mcf of gas, alongside a declared cash distribution of US$0.286230 per unit payable on March 30, 2026, to unitholders of record on March 16, 2026. This combination of slightly higher oil volumes, lower gas output, and a fresh income payout detail gives investors a clearer view of near-term cash flows from the trust’s underlying assets. We’ll now examine how the latest production mix and...

PulteGroup recently announced the past nomination of Benjamin Schall, CEO and President of AvalonBay Communities, as an independent director to its Board, adding multifamily real estate and capital allocation expertise to its governance mix. At the same time, renewed attention on PulteGroup’s alignment with Peter Lynch-style GARP filters has highlighted its combination of earnings growth history, valuation metrics, profitability, and balance sheet strength, drawing interest from investors...

Protalix BioTherapeutics FY 2025 Earnings Snapshot Protalix BioTherapeutics (PLX) has wrapped up FY 2025 with fourth quarter revenue of US$9.1 million and a basic EPS loss of US$0.07, as investors weigh the latest numbers against the share price of US$2.21. The company has seen quarterly revenue move from US$18.2 million in Q4 2024 to US$10.1 million in Q1 2025, US$15.7 million in Q2 2025, US$17.9 million in Q3 2025 and US$9.1 million in Q4 2025. Basic EPS shifted from US$0.09 in Q4 2024 to...